Ingredients By Nature is pleased to announce the recently published study on its triple-patented, lemon flavonoid blend, Eriomin®. The study published in Frontiers in Nutrition (Volume 12, Article 1639901) is a groundbreaking clinical trial that demonstrated Eriomin in combination with metformin was a safe and effective nutritional adjunct to metformin in the early management of hyperglycemia.
The 26-week, double-blind, randomized, placebo-controlled, crossover study, involving 71 prediabetic men and women (ages 18–65), tested daily supplementation of 250mg of Eriomin alongside metformin (1,000 mg/day). The results demonstrated improved postprandial glucose metabolism, including a 5% reduction in 2-h OGTT glucose and preservation of active GLP-1 levels. In contrast, the placebo group exhibited a decline in GLP-1 and increased insulin resistance. The Eriomin group also showed a 12% reduction in TNF-α, a 7.5% increase in plasma antioxidant capacity (FRAP), and modest but significant decreases in body weight, fat mass, and BMI (all p ≤ 0.05). Additionally, systolic blood pressure was reduced by 4%, potentially associated with improved antioxidant status and higher dietary potassium intake.
“We are thrilled with the outcome of this clinical research. Frequently, there are concerns that medications or supplements might adversely impact each other when taken in conjunction. This study may offer assurances that no adverse interactions were seen when taken by otherwise healthy but metabolically sensitive individuals, said Rob Brewster, President at Ingredients By Nature. “This is the fourth published human clinical study conducted on Eriomin, further backing its significant positive effects in supporting glycemic control, metabolic markers, GLP-1 levels, and antioxidant status.”
Eriomin® is a standardized citrus flavonoid blend primarily composed of eriocitrin. It holds three U.S. patents and represents a promising adjunct for pharmaceutical developers, healthcare practitioners, dietary supplement manufacturers, and food and beverage formulators.
To learn more about Eriomin, its clinical backing, and product versatility, visit https://ingredientsbynature.com.
References:
Cesar T, Oliveira MR, Sandrim V, et al. Citrus flavonoid supplement enhances glycemic and metabolic control in prediabetic patients on metformin: a randomized controlled trial. Frontiers in Nutrition. 2025;12. doi: https://doi.org/10.3389/fnut.2025.1639901
Ribeiro, C. B., Ramos, F. M., Manthey, J. A., & Cesar, T. B. (2019). Effectiveness of Eriomin® in managing hyperglycemia and reversal of prediabetes condition: A double-blind, randomized, controlled study. Phytotherapy Research, 33(7), 1921-1933.
Cesar, T. B., Ramos, F. M. M., & Ribeiro, C. B. (2022). Nutraceutical eriocitrin (Eriomin®) reduces hyperglycemia by increasing glucagon-like peptide 1 and downregulates systemic inflammation: A crossover-randomized clinical trial. Journal of Medicinal Food, 25(11), 1050-1058.
Ramos, F. M., Ribeiro, C. B., Cesar, T. B., Milenkovic, D., Cabral, L., Noronha, M. F., & Sivieri, K. (2023). Lemon flavonoids nutraceutical (Eriomin®) attenuates prediabetes intestinal dysbiosis: A double-blind randomized controlled trial. Food Science & Nutrition, 00, 1-13.
